Phaseline

Companies › Genetix Biotherapeutics

Genetix Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Hematology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lovotibeglogene Autotemcel (bb1111)
Hemoglobin beta chain exogenous gene
HBBPhase 3Sickle Cell DiseaseMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04293185Lovotibeglogene Autotemcel (bb1111)Phase 3Sickle Cell DiseaseHematologyMay 2027

Targets

HBB (1)

Companies with the same targets

Shenzhen Hemogen

Companies built like this

Shanghai Xinzhi BioMed Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Grand Shuyang Life Sciences (Chengdu) Gritgen Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.